$OACB.U News
Last published 4y ago
- 4y agoOACBOACB.UAlvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT04 and Reference Product Stelara®Business WireThe confirmatory clinical, safety and efficacy study for AVT04, biosimilar candidate to Stelara® (ustekinumab) met its primary endpoint AVT04 (ustekinumab) is part of a broader pipeline of Alvotech's biosimilars and biosimilar candidates, which i
- 4y agoOACBOACB.UAlvotech Announces Positive Results from a Pharmacokinetic Similarity Study for AVT04, a Proposed Biosimilar to Stelara®Business Wire- Results from pharmacokinetic (PK) similarity study demonstrate bioequivalence of AVT04 (ustekinumab) to the reference product Stelara® Alvotech Holdings S.A. ("Alvotech"), a global biotech company focused solely on the development and manufacture
- 4y agoOACBOACB.UAlvotech Improves Access to Capital and Streamlines Path to Expected Public Listing on NASDAQ Stock ExchangeBusiness WireAlvotech and Oaktree Acquisition Corp. II establish financing facilities to enhance the company's capital position and to replace any redeemed capital as part of their proposed merger Parties agree to reduce the minimum cash condition outlined in the
- 4y agoOACBOACB.UAlvotech and STADA Pave Way to Launching HUKYNDRA®(AVT02), a Citrate-free, High-concentration Biosimilar to Humira® by Resolving European Patent Dispute With AbbVieBusiness WireUpon launch, HUKYNDRA® will be one of two citrate-free, high-concentration adalimumab biosimilars on the European market All intellectual-property disputes related to market entry of Alvotech's AVT02 (adalimumab) in the U.S. and Europe are n
- 4y agoOACBOACB.UAlvotech and Oaktree Acquisition Corp. II Announce Merger Agreement to Create a Leading Publicly-Traded Global Biopharmaceutical CompanyBusiness WireAlvotech is a leading pure play biosimilar platform focused on the development and manufacture of high-quality biosimilar medicines for global markets. Biosimilars are therapeutic equivalents to biologics, a rapidly growing category of highly efficaci